Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
82.76
+8.71 (11.76%)
At close: Sep 2, 2026, 4:00 PM EDT
82.26
-0.50 (-0.60%)
Pre-market: Sep 3, 2026, 5:48 AM EDT

Tarsus Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
606.33451.36182.9517.4525.8257.03
Revenue Growth
105.17%146.71%948.62%-32.42%-54.73%-
Gross Profit
501.26356.35116.74-34.46-17.7613.24
Operating Income
-48.54-70.97-120.57-143.16-62.71-12.16
Net Income
-46.48-66.42-115.55-135.89-62.09-13.83
Earnings Per Share
-1.08-1.59-3.07-4.62-2.52-0.67
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
449.69417.27291.38227.44217.03171.82
Total Debt
88.8183.0472.4530.2220.161.19
Net Cash (Debt)
360.88334.23218.92197.23196.87170.62
Net Cash Growth
16.90%52.67%11.00%0.18%15.38%1.99%
Net Cash Per Share
8.408.005.826.718.008.30

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
74.16-12.45-83.03-117.49-49.033.75
Capital Expenditures
-18.16-9.86-1.57-1.5-0.51-0.59
Free Cash Flow
56-22.31-84.59-119-49.543.16
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
82.67%78.95%63.81%-197.50%-68.81%23.22%
Operating Margin
-8.00%-15.72%-65.90%-820.53%-242.92%-21.32%
Pretax Margin
-6.49%-14.26%-63.16%-778.89%-240.53%-24.15%
Profit Margin
-7.66%-14.71%-63.16%-778.89%-240.51%-24.25%
FCF Margin
9.24%-4.94%-46.24%-682.04%-191.88%5.54%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-97.48----
P/FCF Ratio
64.85----147.13
PS Ratio
5.997.7011.5738.4215.158.16